Forty years of human G‐CSF: A short history in time

Summary Human G‐CSF was identified in 1984 at Memorial Sloan‐Kettering Cancer Centre, New York. Based on these findings, recombinant G‐CSF was developed by Amgen, Thousand Oaks. In 1987, clinical trials began using recombinant G‐CSF in cancer patients following chemotherapy to reduce the duration of neutropenia and in patients with congenital neutropenia (CN) to increase the number of neutrophils. It has changed the quality of life for many cancer patients and saved the lives of many patients with (CN).